ATE367816T1 - Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten - Google Patents

Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten

Info

Publication number
ATE367816T1
ATE367816T1 AT01933418T AT01933418T ATE367816T1 AT E367816 T1 ATE367816 T1 AT E367816T1 AT 01933418 T AT01933418 T AT 01933418T AT 01933418 T AT01933418 T AT 01933418T AT E367816 T1 ATE367816 T1 AT E367816T1
Authority
AT
Austria
Prior art keywords
estrogen
combination
low doses
immune diseases
treat immune
Prior art date
Application number
AT01933418T
Other languages
English (en)
Inventor
Halina Offner
Original Assignee
Univ Oregon Health & Science
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Us Government filed Critical Univ Oregon Health & Science
Application granted granted Critical
Publication of ATE367816T1 publication Critical patent/ATE367816T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT01933418T 2000-05-12 2001-05-11 Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten ATE367816T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20398000P 2000-05-12 2000-05-12

Publications (1)

Publication Number Publication Date
ATE367816T1 true ATE367816T1 (de) 2007-08-15

Family

ID=22756094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933418T ATE367816T1 (de) 2000-05-12 2001-05-11 Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten

Country Status (7)

Country Link
US (3) US7371385B2 (de)
EP (1) EP1286664B1 (de)
AT (1) ATE367816T1 (de)
AU (2) AU2001259847B9 (de)
CA (1) CA2408935A1 (de)
DE (1) DE60129550T2 (de)
WO (1) WO2001085154A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
WO2008150547A1 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
WO2002094276A1 (en) 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
WO2002094278A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
CA2448278C (en) 2001-05-23 2010-06-08 Christian Franz Holinka Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
ES2278925T3 (es) 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
EP1358881A1 (de) 2002-04-30 2003-11-05 Schering Aktiengesellschaft Verwendung von biogenen Estrioldiester-Prodrugs zur Behandlung von Autoimmunkrankheiten
EP1358882A1 (de) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Verwendung von Prodrogue von Estriol sulfamate zur Behandlung von autoimmunischen Erkrankungen
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
ES2274252T3 (es) * 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
WO2004006936A1 (en) 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CA2512021A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
JP2008500368A (ja) * 2004-05-27 2008-01-10 ミジェニックス コーポレイション 細胞保護のための２置換１７−イミノエストロゲン化合物
EP2270512B1 (de) * 2004-12-08 2016-03-23 Cedars-Sinai Medical Center Verfahren zur Diagnose von Morbus Crohn
WO2007127981A2 (en) * 2006-04-28 2007-11-08 University Of Rochester Analyte-releasing beads and use thereof in quantitative elispot or fluorispot assay
EP2114412B1 (de) 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2010055513A1 (en) * 2008-11-13 2010-05-20 Eve Medical Systems Ltd. Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
US8609605B2 (en) * 2009-03-17 2013-12-17 Cardiovax, Llc Immunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100
US10845363B2 (en) * 2012-11-27 2020-11-24 DeePath Medical Diagnostics, Inc. Cell-specific signaling biomarker analysis by high parameter cytometry; sample processing, assay set-up, method, analysis
WO2014085679A1 (en) * 2012-11-27 2014-06-05 Deepath Medical Inc. Methods and combinations of signaling markers for assessment of disease states
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (de) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
EP3430172A4 (de) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center Verfahren zur diagnose einer entzündlichen darmerkrankung durch rnaset2
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US183299A (en) * 1876-10-17 Improvement in devices for securing fence-wire to posts
US614192A (en) * 1898-11-15 Automatic locking device for chairs
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US6039947A (en) * 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
WO1994020120A1 (en) * 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
JPH10175854A (ja) * 1996-10-18 1998-06-30 Dokutaazu Kosumeteikusu:Kk 津液改善用皮膚外用剤
SK12412000A3 (sk) * 1998-02-23 2002-05-09 Neurocrine Biosciences, Inc. Metódy liečenia diabetu použitím peptidových analógov inzulínu
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
DE19821289A1 (de) 1998-05-13 1999-11-18 Volkmar Schoellhorn Verfahren zur Bestimmung der Aktivität von menschlichen und tierischen Zellen, insbesondere Blutzellen, und Mikrotiterplatten
US6958327B1 (en) * 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
DK1226155T3 (da) * 1999-11-02 2007-09-10 Bayer Schering Pharma Ag 18-nor-steroider som selektivt virksomme östrogener
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Also Published As

Publication number Publication date
AU2001259847B2 (en) 2006-02-02
WO2001085154A2 (en) 2001-11-15
WO2001085154A3 (en) 2002-08-29
US20080227761A1 (en) 2008-09-18
US20080207580A1 (en) 2008-08-28
WO2001085154A8 (en) 2003-10-30
AU2001259847B9 (en) 2006-08-10
AU5984701A (en) 2001-11-20
DE60129550D1 (de) 2007-09-06
US7371385B2 (en) 2008-05-13
CA2408935A1 (en) 2001-11-15
US7731973B2 (en) 2010-06-08
US7579006B2 (en) 2009-08-25
AU2001259847B8 (en) 2006-02-23
US20030176409A1 (en) 2003-09-18
DE60129550T2 (de) 2008-04-10
EP1286664A2 (de) 2003-03-05
EP1286664B1 (de) 2007-07-25

Similar Documents

Publication Publication Date Title
ATE367816T1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
EA200700500A1 (ru) Совокупность лекарственных форм и способ её введения
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
BRPI0516024A (pt) uso de azd 2171 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of ***e dependency
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
ATE110269T1 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
KR910009267A (ko) 우울증의 치료방법
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
MXPA05010804A (es) Torio 227 para uso en radioterapia de enfermedades del tejido blando.
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
UA36361A (uk) Спосіб лікування захворювань щитовидної залози

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties